A Grunenthal First: Establishing A US Presence With A Tailored Marketing Strategy

15 Nov 2018

• By John Davis

Germany's pain-focused specialty pharmaceutical firm is adding America to its commercial reach, through acquiring New York's Averitas Pharma to jumpstart its push to commercialize products on its own account, via a niche approach.

Broken arm — Complex regional pain syndromes often involve injured extremities. • Source: Shutterstock

By acquiring the small New York-based company, Averitas Pharma, the family-owned European-based specialty company, Grunenthal GMBH, is aiming to use Averitas's experience in a specialty pharmacy and hub services model to commercialize, for the first time, its own portfolio of niche pain-related therapies in the US.

The acquisition confirms that US market opportunities are as much a draw for privately held companies as they are for...